Allergy Asthma Respir Dis.  2015 Mar;3(2):124-127. 10.4168/aard.2015.3.2.124.

Lack of associations between tumor necrosis factor-alpha genetic polymorphism -308G/A and antituberculous drug-induced maculopapular eruption

Affiliations
  • 1Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea. ykjee@dankook.ac.kr
  • 2Department of Internal Medicine, Eulji University College of Medicine, Seoul, Korea.
  • 3Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.

Abstract

PURPOSE
Adverse cutaneous reactions to antituberculous drugs (ATD), such as maculopapular eruption (MPE), are the most common causes of discontinuation of scheduled treatment of tuberculosis. We previously reported that tumor necrosis factor (TNF)-alpha genetic polymorphism -308G/A is significantly associated with ATD-induced hepatitis. This study aimed to investigate associations between TNF-alpha -308G/A and ATD-induced MPE.
METHODS
Patients with ATD-induced MPE and controls without any adverse reactions to ATD were recruited from the database of the Adverse Drug Reaction Pharmacogenomic Research Group database of Korea. We compared the genotype frequency of TNF-alpha-308G/A between patients with ATD-induced MPE and ATD-tolerant controls.
RESULTS
A total of 69 patients with ATD-induced MPE and 229 control subjects were enrolled for this study. There were no significant differences in genotype frequency between the patients and the controls, suggesting lack of associations between TNF-alpha-308G/A and ATD-induced MPE.
CONCLUSION
The TNF-alpha genetic polymorphism -308G/A may not be related to the development of ATD-induced MPE, in contrast to ATD-induced hepatitis. These findings suggest that associations between TNF-alpha-308G/A and ATD-induced adverse reactions can be phenotype-specific.

Keyword

Genetic polymorphism; Tumor necrosis factor-alpha; Antitubercular agents; Drug eruption

MeSH Terms

Antitubercular Agents
Drug Eruptions
Drug-Related Side Effects and Adverse Reactions
Genotype
Hepatitis
Humans
Korea
Polymorphism, Genetic*
Tuberculosis
Tumor Necrosis Factor-alpha*
Antitubercular Agents
Tumor Necrosis Factor-alpha

Cited by  1 articles

Interpretation of negative results in genetic epidemiology
Heung-Woo Park
Allergy Asthma Respir Dis. 2015;3(2):93-94.    doi: 10.4168/aard.2015.3.2.93.


Reference

1. Korea Centers for Disease Control & Prevention. Annual report on the tuberculosis cases notified in Korea 2012. Cheongwon: Korean Centers for Disease Control & Prevention;2013.
2. American Thoracic Society. CDC. Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep. 2003; 52(RR-11):1–77.
3. Kim SH, Lee BH, Lee KD, Park JS, Kim YS, Jee YK, et al. The prevalence of adverse drug reactions to a short course anti-tuberculosis regimen. Korean J Med. 2007; 73:496–502.
4. Tan WC, Ong CK, Kang SC, Razak MA. Two years review of cutaneous adverse drug reaction from first line anti-tuberculous drugs. Med J Malaysia. 2007; 62:143–146.
5. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003; 167:1472–1477.
Article
6. Dossing M, Wilcke JT, Askgaard DS, Nybo B. Liver injury during antituberculosis treatment: an 11-year study. Tuber Lung Dis. 1996; 77:335–340.
Article
7. Roychowdhury S, Svensson CK. Mechanisms of drug-induced delayed-type hypersensitivity reactions in the skin. AAPS J. 2005; 7:E834–E846.
Article
8. Kim SH, Kim SH, Yoon HJ, Shin DH, Park SS, Kim YS, et al. TNF-α genetic polymorphism -308G/A and antituberculosis drug-induced hepatitis. Liver Int. 2012; 32:809–814.
Article
9. Kim SH, Kim SH, Yoon HJ, Shin DH, Park SS, Kim YS, et al. GSTT1 and GSTM1 null mutations and adverse reactions induced by antituberculosis drugs in Koreans. Tuberculosis (Edinb). 2010; 90:39–43.
Article
10. Lee YH, Harley JB, Nath SK. Meta-analysis of TNF-alpha promoter -308 A/G polymorphism and SLE susceptibility. Eur J Hum Genet. 2006; 14:364–371.
Article
11. Elahi MM, Asotra K, Matata BM, Mastana SS. Tumor necrosis factor alpha -308 gene locus promoter polymorphism: an analysis of association with health and disease. Biochim Biophys Acta. 2009; 1792:163–172.
Article
12. Lu Z, Chen L, Li H, Zhao Y, Lin L. Effect of the polymorphism of tumor necrosis factor-alpha-308 G/A gene promoter on the susceptibility to ulcerative colitis: a meta-analysis. Digestion. 2008; 78:44–51.
Article
13. Fernandez TD, Mayorga C, Torres MJ, Cornejo-Garcia JA, Lopez S, Chaves P, et al. Cytokine and chemokine expression in the skin from patients with maculopapular exanthema to drugs. Allergy. 2008; 63:712–719.
Article
14. Magee P. Drug-induced skin disorders. In : Walker R, Edwards C, editors. Clinical pharmacy and therapeutics. 3rd ed. Phildelphia: Churchill Livingstone;2003. p. 843–852.
15. Lehloenya RJ, Dheda K. Cutaneous adverse drug reactions to anti-tuberculosis drugs: state of the art and into the future. Expert Rev Anti Infect Ther. 2012; 10:475–486.
Article
16. Kim SH, Lee SK, Kim SH, Park HW, Chang YS, Lee KW, et al. Antituberculosis drug-induced hypersensitivity syndrome and its association with human leukocyte antigen. Tuberculosis (Edinb). 2013; 93:270–274.
Article
17. Kim SH, Kim SH, Yoon HJ, Shin DH, Park SS, Kim YS, et al. NAT2, CYP2C9, CYP2C19, and CYP2E1 genetic polymorphisms in anti-TB drug-induced maculopapular eruption. Eur J Clin Pharmacol. 2011; 67:121–127.
Article
Full Text Links
  • AARD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr